Pure Global AI
NCT06035406Not yet recruiting

A Trial of SP2086 With Hepatic Insufficiency

Pharmacokinetics and Safety of SP2086 in Subjects With Mild and Moderate Liver Impairment and Normal Liver Function.
Jiangsu HengRui Medicine Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes
Drug/Device/Intervention
Retagliptin Phosphate Tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu HengRui Medicine Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2023
End date
Dec 01, 2023
Enrollment
24 participants
Primary outcome

PK parameters：Cmax；,PK parameters：AUC0-t；,PK parameters：AUC0-∞；

Summary

This study used a single-dose, open design to compare the pharmacokinetics of subjects with
 mild and moderate liver impairment and subjects with normal liver function.

ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsOther specified diabetes mellitus without complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06035406
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06035406 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Diabetes. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.